Trials / Completed
CompletedNCT04787211
A Study of Human Monoclonal Antibodies, BRII-196 and BRII-198
A Phase 2 Study to Evaluate the Safety and Efficacy of Human Monoclonal Antibodies, BRII-196 and BRII-198, Administered by Intravenous Infusion for the Treatment of COVID-19 Patients
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- Brii Biosciences Limited · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this phase 2 study is to evaluate the safety and efficacy of single dose IV infusion of BRII-196 and BRII-198 given as combination therapy in patients with severe COVID-19, and mild to moderate COVID-19 and asymptomatic carrier.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BRII-196 and BRII-198 | BRII-196 and BRII-198 given by intravenous administration |
| DRUG | Placebo | Placebo given by intravenous administration |
Timeline
- Start date
- 2021-06-20
- Primary completion
- 2021-12-02
- Completion
- 2021-12-02
- First posted
- 2021-03-08
- Last updated
- 2023-03-03
Locations
6 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04787211. Inclusion in this directory is not an endorsement.